Intervention

Brexpiprazole

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 35 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials35

Recruiting2

Common conditions25

Lead sponsors shown11

Clinical trials

35 shown

Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive DisordersNCT05962216 · 2023-07-01

Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)NCT05017311 · 2023-01-20

Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in SchizophreniaNCT07715253 · 2026-12-01

NOT_YET_RECRUITING

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and AnxietyNCT05504486 · 2022-08-29

Real-life Assessment of Abilify Maintena + Rexult in SchizophreniaNCT05169268 · 2022-02-01

Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive DisorderNCT04830215 · 2021-04-01

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation StudyNCT04162522 · 2019-12-23

Safety and Efficacy of Brexpiprazole in the Treatment of SchizophreniaNCT03874494 · 2019-11-27

"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"NCT04641780 · 2019-08-17

Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeNCT03724942 · 2018-11-09

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeNCT03594123 · 2018-10-11

A Long-Term Study of Brexpiprazole in Patients With Major Depressive DisorderNCT03737474 · 2018-10-04

Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeNCT03620981 · 2018-08-20

A Study of Brexpiprazole in Patients With Major Depressive DisorderNCT03697603 · 2018-07-30

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive DisorderNCT03538691 · 2018-07-13

Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use DisorderNCT03526354 · 2018-06-19

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive DisorderNCT03487198 · 2018-05-30

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's TypeNCT03548584 · 2018-05-16

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With SchizophreniaNCT03238326 · 2017-08-23

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With ImpulsivityNCT02194933 · 2015-02-01

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and IrritabilityNCT02212613 · 2014-09-01

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute SchizophreniaNCT02054702 · 2014-02-01

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive TherapyNCT02012218 · 2013-11-01

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work EnvironmentNCT02013609 · 2013-11-01

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety SymptomsNCT02013531 · 2013-11-01

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode SchizophreniaNCT02013622 · 2013-11-01

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant TherapyNCT01942785 · 2013-10-01

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive DisorderNCT01944969 · 2013-10-01

Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive DisorderNCT01942733 · 2013-09-01

Brexpiprazole in Patients With SchizophreniaNCT01810783 · 2013-07-01

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentNCT01838681 · 2013-06-01

Brexpiprazole in Patients With Acute SchizophreniaNCT01810380 · 2013-03-01

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialNCT01727726 · 2012-12-01

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With SchizophreniaNCT01668797 · 2012-10-01

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive DisorderNCT01670279 · 2012-07-01

Common conditions

Leading sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. 16 H. Lundbeck A/S 6 Otsuka Pharmaceutical Co., Ltd. 4 Otsuka Beijing Research Institute 2 Dr. Albert Kar-Kin Chung 1 New York State Psychiatric Institute 1 Nova Scotia Health Authority 1 Otsuka Pharmaceutical, Inc., Philippines 1 The University of Hong Kong 1 University Health Network, Toronto 1 University of Massachusetts, Worcester 1

Trial status mix

COMPLETED27

RECRUITING2

TERMINATED2

WITHDRAWN2

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE326

PHASE44

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.